A new skin cancer drug could soon become available to more than a million Canadians, and the country is already seeing results.
The U.S. Food and Drug Administration approved the new compound called pomagglutinin (PG), also known as Nexplanon.
The drug was developed by Sanofi-Aventis and is part of a suite of anti-cancer drugs approved by the FDA to fight melanoma and other forms of cancer.
It has not yet been approved for other types of skin cancer.
A patient could be treated with PG before they are diagnosed with cancer, said the company.
The product is designed to help patients who are in remission and have no other treatment options.
Patients can start using PG as early as six months after receiving a diagnosis of cancer or their first treatment with an approved drug, according to Sanofi.
The drug is available in three formulations, and patients can choose from three different strengths and colors.PG has not been approved by any other regulatory body, but is in the pipeline.
The company expects to begin testing PG for its first patients in 2018, the company said in a statement.
The new drug will be approved by Health Canada and the Food and Drugs Administration.PG will be marketed under the brand name Nexplanin, which is derived from Nexplanium, a plant that grows naturally in China.
The new drug is expected to be available for up to $15,000 a year.
Nexplanon was developed to combat melanoma, which can grow on the skin and cause cancerous growths.
It also helps to combat other forms, such as skin cancer and cancers of the digestive system.
The Canadian Food Inspection Agency said in its news release that PG has not received approval for use in other types and conditions.
It is also not available in other countries.